L'audio di questo episodio potrebbe essere danneggiato.
How to fix it?
INFORMAZIONI SU QUESTO EPISODIO
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Inglese
Stati Uniti
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
ALTRI EPISODI IN QUESTO PODCAST
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da U.S. Food and Drug Administration, Center for Drug Evaluation and Research, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
